A groundbreaking multinational investigation into cholesterol management is challenging the long-standing medical dogma that “lower is better” in cardiovascular risk prevention. The innovative study, recently summarized in a commentary published in the prestigious journal Engineering, uncovers complex, population-specific relationships between cholesterol levels and mortality risk, particularly among Chinese adults. This paradigm-shifting research sheds new light on cholesterol’s multifaceted role in human health, advocating for a nuanced approach to lipid regulation that balances cardiovascular benefits with cancer and all-cause mortality risks.
For decades, clinical guidelines worldwide have emphasized lowering low-density lipoprotein cholesterol (LDL-C) as the primary strategy for preventing atherosclerotic cardiovascular disease (CVD). This principle has underpinned statin therapy prescriptions and lipid management protocols globally. However, emerging evidence has painted a more intricate biological picture. Very low LDL-C concentrations have been linked to an increased incidence of cancer and a curious U-shaped association with all-cause mortality, wherein both low and high cholesterol levels correlate with poorer outcomes. Until now, these findings have been muddied by confounding factors such as lipid-lowering medication effects and underlying comorbidities, making clinical translation challenging.
The recent large-scale prospective study, analyzed by researchers Jiang et al., involved an unprecedented cohort of over 480,000 adults, with 163,115 Chinese and 317,305 UK participants followed longitudinally for nearly a decade. Crucially, the study focused on individuals free from lipid-lowering therapies and severe chronic illnesses at baseline to minimize reverse causality and confounding influences. This rigorous design facilitated a clear examination of inherent cholesterol-mortality relationships without pharmaceutical interference or illness-driven lipid alterations.
In the Chinese cohort, the researchers discovered a striking U-shaped association between total cholesterol (TC), LDL-C, and non-high-density lipoprotein cholesterol (non-HDL-C) levels and all-cause mortality. Elevated cholesterol correlated with increased coronary heart disease mortality, consistent with the atherogenic role of lipids. However, paradoxically, lower cholesterol levels were linked to heightened risks of all-cause mortality and certain cancers — notably gastrointestinal and urological malignancies. The data also revealed that LDL-C levels below 70 mg/dL and TC under 120 mg/dL were independently associated with increased hemorrhagic stroke risk, regardless of nutritional status or body mass index.
This nuanced risk spectrum prompted the study authors to identify “optimal” cholesterol thresholds specific to the Chinese population: 200 mg/dL for TC, 130 mg/dL for LDL-C, and 155 mg/dL for non-HDL-C. These values correspond closely to the borderline-high categories in existing guidelines and suggest that extremely low cholesterol could be detrimental. Contrastingly, the UK cohort exhibited markedly higher optimal thresholds—250 mg/dL for TC, 175 mg/dL for LDL-C, and 200 mg/dL for non-HDL-C—with an L-shaped mortality curve. In this population, increased cholesterol was not associated with significantly elevated mortality, a pattern the authors attribute to differences in baseline lipid profiles, superior cardiovascular management, overall healthier status, and inherent genetic variability.
Additionally, the study explored the prognostic significance of longitudinal cholesterol changes. Within the Chinese group, individuals maintaining persistently low TC, LDL-C, or non-HDL-C—or those exhibiting declining cholesterol levels from low or medium baselines—demonstrated higher all-cause mortality risk compared to participants with stable, medium-range cholesterol. These dynamics were absent in the UK data, potentially reflecting sample size constraints or population-specific biological mechanisms. The authors postulate that unexplained reductions in cholesterol among untreated individuals may be harbingers of underlying health deterioration manifesting as aging, malnutrition, or frailty, warranting vigilant clinical monitoring.
This comprehensive work boasts multiple strengths, including its extensive, ethnically diverse sample size, nearly ten years of follow-up, inclusion of untreated participants to limit bias, repeated cholesterol measurements, and sophisticated dose-response analyses of cholesterol and mortality. However, the authors acknowledge important limitations, such as a lack of sex-specific mortality stratification and insufficient data to dissect genetic risk variability comprehensively. These gaps highlight crucial areas for future investigation.
The implications of these findings reverberate profoundly across cardiovascular and oncology fields, urging a shift from the ubiquitous “lower is better” paradigm towards individualized cholesterol management strategies. By calibrating treatment targets to population-specific thresholds informed by robust epidemiological evidence, clinicians can balance the dual imperatives of minimizing cardiovascular risk without inadvertently increasing cancer or non-CVD mortality. This precision medicine approach promises to optimize patient outcomes, especially in East Asian populations traditionally underrepresented in lipid research.
Moreover, the discovery of cholesterol’s complex, bidirectional association with mortality underlines the essential need for clinicians to interpret lipid profiles within the broader context of patient health, nutritional status, and potential comorbidities. Identifying and investigating unexplained low cholesterol or sharp declines in lipid levels may unmask occult disease or frailty, enabling early interventions beyond lipid management alone.
This landmark study fundamentally challenges a cornerstone of cardiovascular prophylaxis, demonstrating that extreme cholesterol lowering is not universally beneficial and may carry unintended risks, particularly in specific ethnicities and health contexts. As the global burden of chronic diseases continues to evolve, tailoring cholesterol management to reflect nuanced biological relationships and demographic diversity emerges as a critical priority for clinicians and guideline developers worldwide.
Researchers Jianxin Li and Xiangfeng Lu from China’s Fuwai Hospital and National Center for Cardiovascular Diseases authored the insightful commentary synthesizing these findings, underscoring the urgency to move beyond one-size-fits-all lipid targets. Their paper, “Optimizing Cholesterol Management Strategies Based on Cholesterol–Mortality Associations,” presents a compelling case for embracing precision medicine in lipidology. The open access article is available via DOI 10.1016/j.eng.2025.10.004, inviting the global medical community to reconsider entrenched cholesterol paradigms and innovate future prevention strategies.
In conclusion, this pioneering multinational collaboration serves as a clarion call to rethink cholesterol management through the lens of population-specific data, holistic patient evaluation, and dynamic lipid monitoring. Bridging cardiovascular medicine with oncology insights, the study emboldens a paradigm shift from blanket cholesterol reduction to calibrated, evidence-informed therapeutic goals—a transformative step towards truly personalized medicine in cardiovascular and chronic disease prevention.
Subject of Research:
Cholesterol management strategies and their association with all-cause and cause-specific mortality in diverse ethnic populations.
Article Title:
Optimizing Cholesterol Management Strategies Based on Cholesterol–Mortality Associations
News Publication Date:
17-Feb-2026
Web References:
https://doi.org/10.1016/j.eng.2025.10.004
https://www.sciencedirect.com/journal/engineering
References:
Jiang et al., Prospective Longitudinal Study on Cholesterol and Mortality in Chinese and UK Populations (Details referenced within the commentary by Jianxin Li and Xiangfeng Lu).
Image Credits:
Not applicable.
Keywords:
Cholesterol management, LDL-C, mortality, U-shaped association, cardiovascular disease, cancer risk, ethnic differences, precision medicine, lipid thresholds, epidemiology, longitudinal cohort study, East Asian health.
